Search

Displaying results 2841 - 2850 of 10000 in total
  1. Drug

    Fenfluramine

    go.drugbank.com/drugs/DB00574
    ApprovedIllicitInvestigationalWithdrawn

    [A214688, A214691, A214700] Fenfluramine was granted initial FDA approval in 1973 prior to its withdrawal; it was granted a new FDA approval on June 25, 2020, for treatment of patients with Dravet syndrome … from the market in 1997.

    Synonyms: DL-Fenfluramine, 1-(m-trifluoromethyl-phenyl)-2-ethylaminopropane
  2. Drug

    Capivasertib

    go.drugbank.com/drugs/DB12218
    ApprovedInvestigational

    Although endocrine-based therapy is the first line of treatment, resistance eventually emerges, leaving chemotherapy the only but often ineffective treatment left. … metastatic breast cancer with one or more alterations in PIK3CA/AKT1/PTEN gene(s) in combination with [fulvestrant].

  3. Drug

    Paltimatrectinib

    go.drugbank.com/drugs/DB21588
    Investigational

    Paltimatrectinib is under investigation in clinical trial NCT04901806 (Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors). … Paltimatrectinib has a monoisotopic molecular weight of 434.13 Da.

  4. Drug

    Perospirone

    go.drugbank.com/drugs/DB08922
    Investigational

    Dainippon Sumitomo Pharma developed perospirone in Japan in 2001 for the treatment of acute schizophrenia and bipolar mania as well as chronic schizophrenia. … Perospirone is an atypical or second-generation antipsychotic of the azapirone family that antagonizes serotonin 5HT2A receptors and dopamine D2 receptors.

    Categories: Dopamine D2 Receptor AntagonistsSynonyms: cis-N-(4-(4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl)butyl)-1,2-cyclohexanedicarboximide
  5. Drug

    Avacopan

    go.drugbank.com/drugs/DB15011
    ApprovedInvestigational

    [L39850] Avacopan was approved by Health Canada on April 20, 2022.[L41650] … [A240254, A240259, A240264, A240269] Avacopan (formerly CCX168) is an allosteric C5aR antagonist indicated for use in AAV.

  6. Drug

    Tilidine

    go.drugbank.com/drugs/DB13787
    Investigational

    Mixtures: TILIDIN HEXAL COMP D-PUMPE, VALORON N RETARD 200/16MG
  7. Drug

    Acetyl sulfisoxazole

    go.drugbank.com/drugs/DB14033
    ApprovedVet approved

    This process causes an inhibition of bacterial folic acid synthesis and de novo synthesis of purines and pyrimidines, resulting in cell growth arrest and cell death [L2788]. … Sulfisoxazole acetyl is an ester of _sulfisoxazole_, a broad-spectrum sulfanilamide and a synthetic analog of para-aminobenzoic acid (PABA) with antibacterial activity.

  8. Drug

    Seletracetam

    go.drugbank.com/drugs/DB05885
    Investigational

    As of 2010, its production was further halted due to the investigation of a newer antiepileptic agent, brivaracetam. … Food and Drug Administration (FDA) investigated as treatment of epilepsy and partial epilepsy however its development had been put on hold in July 2007.

  9. Drug

    Vusolimogene oderparepvec

    go.drugbank.com/drugs/DB23008
    ApprovedInvestigational

    on anti-PD-1 therapy. … [L64061] The virus is engineered to express a fusogenic glycoprotein derived from gibbon ape leukemia virus (GALV-GP-R–) and human granulocyte-macrophage colony-stimulating factor (GM-CSF), and has its

  10. Drug

    Landiolol

    go.drugbank.com/drugs/DB12212
    ApprovedInvestigational

    [A264733,A264738] First approved in Japan in 2002 [A264758] for the treatment of intraoperative tachyarrhythmias,[A264733] landiolol was approved in Canada in April 2024 [L51938] and in the US in November … [A264733] Compared to other beta-blockers, landiolol possesses unique pharmacodynamic and pharmacokinetic properties, in that it has a rapid onset and short duration of action, and has a greater affinity